SCHEDULE: Aquamarine Financial Reports Stake in Oramed Pharmaceuticals

Aquamarine Financial (Cayman) Ltd has updated its beneficial ownership filing for Oramed Pharmaceuticals Inc., now holding 6.38% of the company's common stock.

Summary

• Aquamarine Financial (Cayman) Ltd has filed an amendment to its Schedule 13G, reporting beneficial ownership of 2,653,567 shares of Oramed Pharmaceuticals Inc. common stock.
• This represents 6.38% of the class of securities.
• The filing indicates sole voting and dispositive power over these shares.
• The date of the event requiring this filing is September 30, 2026.
• The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as neutral to slightly negative, as it primarily reports a change in beneficial ownership without new strategic or financial information.

Positives

• Aquamarine Financial (Cayman) Ltd has a significant stake, indicating investor confidence or strategic interest in Oramed Pharmaceuticals.
• The filing confirms sole voting and dispositive power, suggesting clear control over their investment.

Negatives

• The filing is an amendment to a previous filing, suggesting a change in ownership rather than new operational or financial performance news.
• No new strategic initiatives or financial performance data are disclosed in this filing.

Risks

• Changes in beneficial ownership can sometimes precede activist investor actions or shifts in company strategy, though this filing does not explicitly state such intentions.
• The filing does not provide details on the rationale behind the acquisition or any future plans, leaving the market to speculate on Aquamarine's intentions.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding Oramed Pharmaceuticals' future performance.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11."
• "After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct."

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors accumulating significant stakes in publicly traded companies. This filing indicates Aquamarine Financial's increased interest in Oramed Pharmaceuticals, a company operating in the biotechnology sector, which is characterized by high R&D costs and regulatory hurdles.

Stakeholder Impact

• Shareholders may view the increased stake by Aquamarine Financial as a positive sign of institutional interest, potentially leading to increased scrutiny or strategic input.
• The market may interpret this as a signal of confidence in Oramed Pharmaceuticals' long-term prospects.

Next Steps

• Aquamarine Financial will continue to monitor its investment in Oramed Pharmaceuticals.
• Further filings may be required if Aquamarine Financial's ownership stake changes significantly.

Key Dates

Keywords

Oramed Pharmaceuticals, Aquamarine Financial, Schedule 13G, Beneficial Ownership, Common Stock, Investment